March 2024 in “Research Square (Research Square)” PRP injections don't significantly help with mild to moderate erectile dysfunction.
March 2024 in “Cleveland Clinic journal of medicine” Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
December 2023 in “Revista Urología Colombiana / Colombian Urology Journal” More research is needed to find effective treatments for sickle cell disease-related priapism.
December 2023 in “Research and reports in urology” A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.
June 2023 in “Journal of chemical metrology” A new method found unlisted drugs in two popular hair serums, posing a health risk.
March 2023 in “Trends in Telemedicine & E-health” Medical questionnaires could modernize healthcare by improving access and efficiency but need guidelines to ensure quality care.
January 2022 in “Galenika Medical Journal” Medications improve quality of life for men with lower urinary tract symptoms.
July 2017 in “Clin-Alert” Different medications can cause serious side effects in some people.
April 2016 in “Journal of The American Academy of Dermatology” Some blood pressure medications are linked to a higher risk of skin cancer.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
April 2015 in “Andrology” HNG may help prevent the negative effects of chemotherapy on sperm production and white blood cell counts.
April 2016 in “Journal of The American Academy of Dermatology” Finasteride and SSRIs together increase impotence and low libido risk in men.
December 2016 in “The journal of sexual medicine” Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.
34 citations
,
April 2006 in “PubMed” Tamsulosin is a cost-effective treatment for BPH symptoms.
38 citations
,
January 2005 in “PubMed” Dutasteride effectively treats enlarged prostate with manageable side effects.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
70 citations
,
November 2013 in “The BMJ” Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.
5 citations
,
February 2014 in “Journal of Liquid Chromatography & Related Technologies” Method accurately measures finasteride and tamsulosin in combined drug form.
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
8 citations
,
January 2011 in “Korean Journal of Andrology” The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
1 citations
,
July 2013 in “Clinical Drug Investigation” January 2013 in “Journal of Chengdu Medical College” Tolterodine Tartrate effectively treats overactive bladder symptoms.
November 2025 in “Urology” CPDC offers significant cost savings on men's health medications compared to Medicare and GoodRx.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
5 citations
,
December 2018 in “The Journal of clinical psychiatry/The journal of clinical psychiatry” Tamsulosin may slightly increase dementia risk compared to other treatments for enlarged prostate.
March 2014 in “The Journal of Urology” Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
3 citations
,
January 2012 The method accurately measures Tamsulosin and Finasteride in medication and is suitable for regular quality checks.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
3 citations
,
November 1998 in “PubMed” March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.